OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

Trial Identifier: D5162R00034
Sponsor: AstraZeneca
Start Date: July 2023
Primary Completion Date: June 2029
Study Completion Date: June 2029
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Spain Alicante, Spain
Spain Barcelona, Spain
Spain C rdoba, Spain
Spain Girona, Spain
Spain Gran Canaria, Spain
Spain Granada, Spain
Spain Ja n, Spain
Spain L rida, Spain
Spain La Coru a, Spain
Spain Le n, Spain
Spain M laga, Spain
Spain Madrid, Spain
Spain Murcia, Spain
Spain Ourense, Spain
Spain Palma, Spain
Spain Sabadell, Spain
Spain Salamanca, Spain
Spain Santander, Spain
Spain Santiago de Compostela, Spain
Spain Sevilla, Spain
Spain Tenerife, Spain
Spain Valencia, Spain
Spain Valladolid, Spain
Spain Vigo, Spain
Spain Zaragoza, Spain